EZH2 and mantle cell lymphoma: Multiple EZH2-targeting inhibitors (GSK343 or GSK126, or OR-S1) are being tested in MCL those have shown significant anti-proliferative activity in in vitro and in vivo MCL-PDX models [139, 140].